Differential expression of pde5 in failing and nonfailing human myocardium

Circulation: Heart Failure

Volumn 5, Issue 1, 2012, Pages 79-86

  Shan, Xiaoyin ^a   Quaile, Michael P ^a   Monk, Jeffery K ^a   French, Benjamin ^b   Cappola, Thomas P ^a   Margulies, Kenneth B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cgmp; Contractility; Heart failure; Myocardium; Pde5

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; PHOSPHODIESTERASE V; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; HEART ASSIST DEVICE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE OVERLOAD; HEART VENTRICLE CONTRACTILITY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISCHEMIC CARDIOMYOPATHY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CARDIOMYOPATHY; COMPARATIVE STUDY; DONOR; ENZYMOLOGY; HEART CONTRACTION; HEART TRANSPLANTATION; HEART VENTRICLE; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ADULT; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; HEART TRANSPLANTATION; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; SEVERITY OF ILLNESS INDEX; TISSUE DONORS; TRANSPLANTATION;

EID: 84859628031     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.961706     Document Type: Article

References (28)

1. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res. 2007;100:309-327.
2. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689-702. (Pubitemid 44151606)
3. Biel M, Zong X, Ludwig A, Sautter A, Hofmann F. Structure and function of cyclic nucleotide-gated channels. Rev Physiol Biochem Pharmacol. 1999;135:151-171.
4. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: Target of sildenafil. J Biol Chem. 1999;274:13729-13732.
5. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem. 2000; 267:2760-2767. (Pubitemid 30304274)
6. Turko IV, Francis SH, Corbin JD. Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J. 1998;329(Pt 3):505-510. (Pubitemid 28055171)
7. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D. Direct activation of PDE5 by cGMP: Long-term effects within NO/cGMP signaling. J Cell Biol. 2003;160:719-727. (Pubitemid 36298267)
8. Lin CS. Tissue expression, distribution, and regulation of PDE5. Int J Impot Res. 2004;16 Suppl 1:S8-S10.
9. Ramani GV, Park MH. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2010;4:61-70.
10. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res. 2005;96:100-109. (Pubitemid 40095759)
11. Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, Nielsen-Kudsk JE. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail. 2008;10:1158-1165.
12. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem. 2005;280: 12944-12955.
13. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol. 2009;46:560-567.
14. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248. (Pubitemid 47196559)
15. Schafer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res. 2009;82:30-39.
16. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222. (Pubitemid 40321358)
17. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119:408-416.
18. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, dos Remedios C, Pritzker M, Hall JL, Garry DJ, Chen Y. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation. 2010;121:1474-1483.
19. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 Inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17.
20. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two- Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2: 358-367.
21. Saxena N, Rajagopalan N, Edelman K, Lopez-Candales A. Tricuspid annular systolic velocity: A useful measurement in determining right ventricular systolic function regardless of pulmonary artery pressures. Echocardiography. 2006;23:750-755. (Pubitemid 44450529)
22. Shan X, Wang H, Margulies KB. Apoptosis signal-regulating kinase 1 attenuates atrial natriuretic peptide secretion. Biochemistry. 2008;47: 10041-10048.
23. Quaile MP, Kubo H, Kimbrough CL, Douglas SA, Margulies KB. Direct inotropic effects of exogenous and endogenous urotensin-II: Divergent actions in failing and nonfailing human myocardium. Circ Heart Fail. 2009;2:39-46.
24. Selvetella G, Hirsch E, Notte A, Tarone G, Lembo G. Adaptive and maladaptive hypertrophic pathways: Points of convergence and divergence. Cardiovasc Res. 2004;63:373-380. (Pubitemid 38970181)
25. Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane MO, Schini-Kerth VB, Lugnier C. Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS One. 2010;5:e14227.
26. Vandeput F, Krall J, Ockaili R, Salloum FN, Florio V, Corbin JD, Francis SH, Kukreja RC, Movsesian MA. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009;330:884-891.
27. Hassan MA, Ketat AF. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol. 2005;5:10.
28. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009;53:207-215.